First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Guardant Health: the setup is constructive — Shield colorectal cancer screening test adoption metrics - quarterly test volumes, physician ordering patterns…
Watch on earnings: Shield quarterly test volumes and sequential growth rates versus 100M+ addressable screening population, Medicare coverage determination timeline and reimbursement rate finalization for Shield screening, Guardant360 precision oncology test volumes and market share versus Foundation Medicine and tissue biopsy alternatives.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $1.3B to $1.7B as shield colorectal cancer screening test adoption metrics - quarterly test volumes, physician ordering patterns.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.